Citi concludes Lundbeck's PTSD treatment has limited potential
Lundbeck and Otsuka Pharmaceutical have submitted an application to the FDA for the use of Rexulti for the treatment of post-traumatic stress disorder, PTSD.
by MARKETWIRE
Although the market is relatively large, there is only modest potential for Lundbeck in the treatment of post-traumatic stress disorder, commonly known as PTSD, major US bank Citi concludes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
